Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782203 | 0.85 | DGAT1 (0.42) | HCAR3MGAMAMY1AGAASI | |
| SCHEMBL23119752 | 0.84 | HCAR3 (0.63) | HCAR3PTGER4RAB9APOLBDYRK1A | |
| SCHEMBL8237029 | 0.83 | HCAR3 (0.46) | HCAR3RAB9APTK2MAPTNPC1 | |
| SCHEMBL23119707 | 0.76 | HCAR3 (0.58) | HCAR3MGAMAMY1AGAASI | |
| SCHEMBL13889342 | 0.75 | MAOB (0.38) | PTGER4RAB9AMAPTDYRK1ANPC1 | |
| SCHEMBL26645068 | 0.74 | DGAT1 (0.42) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL31473688 | 0.72 | HCAR3 (0.52) | HCAR3PTGER4RAB9APOLBNPC1 | |
| SCHEMBL20529672 | 0.72 | HCAR3 (0.52) | HCAR3PTGER4RAB9APOLBNPC1 | |
| SCHEMBL13180441 | 0.72 | MAPT (0.44) | PTGER4MAPTDYRK1A | |
| SCHEMBL25339436 | 0.71 | PTK2 (0.50) | HCAR3MGAMAMY1AGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | HCAR3 746/4885PTGER4 739/4885MGAM 634/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | HCAR3 746/4885PTGER4 739/4885MGAM 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.